A novel CDK7 inhibitor of the pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2062-2071

  Hutterer, Corina ^a   Eickhoff, Jan ^b   Milbradt, Jens ^a   Korn, Klaus ^a   Zeitträger, Isabel ^a   Bahsi, Hanife ^a   Wagner, Sabrina ^a   Zischinsky, Gunther ^b   Wolf, Alexander ^b   Degenhart, Carsten ^b   Unger, Anke ^b   Baumann, Matthias ^b   Klebl, Bert ^b   Marschall, Manfred ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Lead Discovery Center GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LDC 4297; PROTEIN SERINE THREONINE KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; CYCLIN-DEPENDENT KINASE 7, MOUSE; LDC4297; PYRAZOLE DERIVATIVE;

ADENOVIRIDAE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; EFFECTIVE CONCENTRATION; FIBROBLAST; GENE EXPRESSION; HERPESVIRIDAE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; ORTHOMYXOVIRIDAE; POXVIRIDAE; PRIORITY JOURNAL; RETROVIRIDAE; VIRUS CELL INTERACTION; VIRUS INACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CYTOMEGALOVIRUS; DRUG EFFECTS; GENE EXPRESSION REGULATION; MOUSE; PHOSPHORYLATION; VIROLOGY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; CYTOMEGALOVIRUS; FIBROBLASTS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRIDAE; HUMANS; MICE; PHOSPHORYLATION; PYRAZOLES; TRIAZINES; VIRUS REPLICATION;

EID: 84949115517     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04534-14     Document Type: Article

References (51)

1. Bregman DB, Pestell RG, Kidd VJ. 2000. Cell cycle regulation and RNA polymerase II. Front Biosci 5:244-257.
2. Fisher RP. 2005. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118:5171-5180. http://dx.doi.org/10.1242/jcs.02718.
3. Schachter MM, Fisher RP. 2013. The CDK-activating kinase Cdk7: taking yes for an answer. Cell Cycle 12:3239-3240. http://dx.doi.org/10.4161/cc.26355.
4. Hirose Y, Ohkuma Y. 2007. Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem 141:601-608. http://dx.doi.org/10.1093/jb/mvm090.
5. Larochelle S, Amat R, Glover-Cutter K, Sansó M, Zhang C, Allen JJ, Shokat KM, Bentley DL, Fisher RP. 2012. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol 19:1108-1115. http://dx.doi.org/10.1038/nsmb.2399.
6. Ganuza M, Sáiz-Ladera C, Cañamero M, Gómez G, Schneider R, Blasco MA, Pisano D, Paramio JM, Santamaría D, Barbacid M. 2012. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J 31:2498-2510. http://dx.doi.org/10.1038/emboj.2012.94.
7. Lolli G, Johnson LN. 2005. CAK-cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle 4:572-577.
8. Schang LM. 2002. Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother 50:779-792. http://dx.doi.org/10.1093/jac/dkf227.
9. Zydek M, Hagemeier C, Wiebusch L. 2010. Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle. PLoS Pathog 6:e1001096. http://dx.doi.org/10.1371/journal.ppat.1001096.
10. Schang LM. 2004. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim Biophys Acta 1697:197-209. http://dx.doi.org/10.1016/j.bbapap. 2003.11.024.
11. Tamrakar S, Kapasi AJ, Spector DH. 2005. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7. J Virol 79:15477-15493. http://dx.doi.org/10.1128/JVI.79.24.15477-15493.2005.
12. Kapasi AJ, Spector DH. 2008. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome. J Virol 82:394-407. http://dx.doi.org/10.1128/JVI.01681-07.
13. Marschall M, Freitag M, Weiler S, Sorg G, Stamminger T. 2000. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob Agents Chemother 44:1588-1597. http://dx.doi.org/10.1128/AAC.44.6.1588-1597.2000.
14. Sampaio KL, Cavignac Y, Stierhof YD, Sinzger C. 2005. Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J Virol 79:2754-2767. http://dx.doi.org/10.1128/JVI.79.5.2754-2767.2005.
15. McGregor A, Schleiss MR. 2001. Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. Mol Genet Metab 72:15-26. http://dx.doi.org/10.1006/mgme.2000.3102.
16. Smith LM, McWhorter AR, Masters LL, Shellam GR, Redwood AJ. 2008. Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus. J Virol 82:6689-6696. http://dx.doi.org/10.1128/JVI.00160-08.
17. Tang H, Kawabata A, Yoshida M, Oyaizu H, Maeki T, Yamanishi K, Mori Y. 2010. Human herpesvirus 6 encoded glycoprotein Q1 gene is essential for virus growth. Virology 407:360-367. http://dx.doi.org/10.1016/j.virol.2010.08.018.
18. Elliott G, O'Hare P. 1999. Live-cell analysis of a green fluorescent proteintagged herpes simplex virus infection. J Virol 73:4110-4119.
19. Takahashi M, Otsuka T, Okuno Y, Asano T, Yazahi T, Isomura S. 1974. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet ii: 1288-1290.
20. Auerochs S, Korn K, Marschall M. 2011. A reporter system for Epstein-Barr virus (EBV) lytic replication: anti-EBV activity of the broad antiherpesviral drug artesunate. J Virol Methods 173:334-339. http://dx.doi.org/10.1016/j.jviromet.2011.03.005.
21. Kindsmüller K, Schreiner S, Leinenkugel F, Groitl P, Kremmer E, Dobner T. 2009. A 49-kilodalton isoform of the adenovirus type 5 early region 1B 55-kilodalton protein is sufficient to support virus replication. J Virol 83:9045-9056. http://dx.doi.org/10.1128/JVI.00728-09.
22. Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, Corbeil J. 1997. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A 94:4653-4658. http://dx.doi.org/10.1073/pnas.94.9.4653.
23. Marschall M, Bootz A, Wagner S, Dobner T, Herz T, Kramer B, Leban J, Vitt D, Stamminger T, Hutterer C, Strobl S. 2013. Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis. Antivir Res 100:640-648. http://dx.doi.org/10.1016/j.antiviral.2013.10.003.
24. Mahmoudian S, Auerochs S, Gröne M, Marschall M. 2009. The influenza A virus proteins PB1 and NS1 are subject to a functionally relevant phosphorylation by protein kinase C. J Gen Virol 90:1392-1397. http://dx.doi.org/10.1099/vir.0.009050-0.
25. Milbradt J, Auerochs S, Korn K, Marschall M. 2009. Sensitivity of human herpesvirus 6 toward the broad-spectrum anti-infective drug artesunate. J Clin Virol 46:24-28. http://dx.doi.org/10.1016/j.jcv. 2009.05.017.
26. Rechter S, König T, Auerochs S, Thulke S, Walter H, Dörnenburg H, Walter C, Marschall M. 2006. Antiviral activity of arthrospira-derived spirulan-like substances. Antivir Res 72:197-206. http://dx.doi.org/10.1016/j.antiviral.2006.06.004.
27. Hutterer C, Wandinger SK, Wagner S, Müller R, Stamminger T, Zeitträger I, Godl K, Baumgartner R, Strobl S, Marschall M. 2013. Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK. Antivir Res 99:139-148. http://dx.doi.org/10.1016/j.antiviral.2013.04.017.
28. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A 95:8245-8250. http://dx.doi.org/10.1073/pnas.95.14.8245.
29. Feichtinger S, Stamminger T, Müller R, Graf L, Klebl B, Eickhoff J, Marschall M. 2011. Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1. J Gen Virol 92:1519-1531. http://dx.doi.org/10.1099/vir.0.030494-0.
30. Schleiss M, Eickhoff J, Auerochs S, Leis M, Abele S, Rechter S, Choi Y, Anderson J, Scott G, Rawlinson W, Michel D, Ensminger S, Klebl B, Stamminger T, Marschall M. 2008. Protein kinase inhibitors of the quinazoline class exert anticytomegaloviral activity in vitro and in vivo. Antivir Res 79:49-61. http://dx.doi.org/10.1016/j.antiviral.2008.01.154.
31. Becke S, Fabre-Mersseman V, Aue S, Auerochs S, Sedmak T, Wolfrum U, Strand D, Marschall M, Plachter B, Reyda S. 2010. Modification of the major tegument protein pp65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells. J Gen Virol 91:2531-2541. http://dx.doi.org/10.1099/vir.0.022293-0.
32. Webel R, Milbradt J, Auerochs S, Schregel V, Held C, Nöbauer K, Razzazi-Fazeli E, Jardin C, Wittenberg T, Sticht H, Marschall M. 2011. Two isoforms of the protein kinase pUL97 of human cytomegalovirus are differentially regulated in their nuclear translocation. J Gen Virol 92:638-649. http://dx.doi.org/10.1099/vir.0.026799-0.
33. Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, Klebl B, Meisterernst M. 2014. CDK7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression and survival of tumor cells. Mol Cell Biol 34:3675-3688. http://dx.doi.org/10.1128/MCB.00595-14.
34. Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS. 2013. Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol 20:146-159. http://dx.doi.org/10.1016/j.chembiol.2012.12.006.
35. Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2012. In vitro evaluation of the activities of the novel anti-cytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 56:1135-1137. http://dx.doi.org/10.1128/AAC.05908-11.
36. Hertel L, Rolle S, De Andrea M, Azzimonti B, Osello R, Gribaudo G, Gariglio M, Landolfo S. 2000. The retinoblastoma protein is an essential mediator that links the interferon-inducible 204 gene to cell-cycle regulation. Oncogene 19:3598-3608. http://dx.doi.org/10.1038/sj.onc.1203697.
37. Hume AJ, Finkel JS, Kamil JP, Coen DM, Culbertson MR, Kalejta RF. 2008. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320:797-799. http://dx.doi.org/10.1126/science.1152095.
38. Prichard MN, Sztul E, Daily SL, Perry AL, Frederick SL, Gill RB, Hartline CB, Streblow DN, Varnum SM, Smith RD, Kern ER. 2008. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol 82:5054-5067. http://dx.doi.org/10.1128/JVI.02174-07.
39. Gill RB, Frederick SL, Hartline CB, Chou S, Prichard MN. 2009. Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol J 6:9. http://dx.doi.org/10.1186/1743-422X-6-9.
40. Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van den Bogaard M, Stamminger T. 2002. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J Gen Virol 83:1013-1023.
41. Zimmermann A, Wilts H, Lenhardt M, Hahn M, Mertens T. 2000. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antivir Res 48:49-60. http://dx.doi.org/10.1016/S0166-3542 (00) 00118-2.
42. Bisteau X, Paternot S, Colleoni B, Ecker K, Coulonval K, De Groote P, Declercq W, Hengst L, Roger PP. 2013. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point. PLoS Genet 9:e1003546. http://dx.doi.org/10.1371/journal.pgen. 1003546.
43. Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN. 2012. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 14:870-881. http://dx.doi.org/10.1093/neuonc/nos114.
44. Morgan DO. 2007. The cell cycle: principles of control. New Science Press, London, United Kingdom.
45. Adams PD. 2001. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 1471:M123-M133.
46. Kamil JH, Hume AJ, Jurak I, Münger K, Kalejta RF, Coen DM. 2009. Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase. Proc Natl Acad Sci U S A 106:16823-16828. http://dx.doi.org/10.1073/pnas.0901521106.
47. Chou S, Van Wechel LC, Marousek GI. 2006. Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob Agents Chemother 50:2557-2559. http://dx.doi.org/10.1128/AAC.00207-06.
48. Marschall M, Feichtinger S, Milbradt J. 2011. Regulatory roles of protein kinases in cytomegalovirus replication. Adv Virus Res 80:69-101. http://dx.doi.org/10.1016/B978-0-12-385987-7.00004-X.
49. Kuny CV, Chinchilla K, Culbertson MR, Kalejta RF. 2010. Cyclindependent kinase-like function is shared by the beta and gamma subsets of the conserved herpesvirus protein kinases. PLoS Pathog 6:e1001092.10.1371. http://dx.doi.org/10.1371/journal.ppat.1001092.
50. Rechter S, Scott GM, Eickhoff J, Zielke K, Auerochs S, Müller R, Stamminger T, Rawlinson WD, Marschall M. 2009. Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity. J Biol Chem 284:8605-8613. http://dx.doi.org/10.1074/jbc. M805693200.
51. Guha M. 2012. Cyclin-dependent kinase inhibitors move into phase III. Nat Rev Drug Discov 11:892-894. http://dx.doi.org/10.1038/nrd3908.